Advertisement
Screener

NewAmsterdam Pharma Company N.V. (NAMS) Cash Flows From Used In Investing Activities

NewAmsterdam Pharma Company N.V. Cash Flows From Used In Investing Activities

NewAmsterdam Pharma Company N.V. (NAMS) reported Cash Flows From Used In Investing Activities of EUR 5.17 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-08-07.

Financial Statements › Cash Flow › Investing Activities

ifrs-full:CashFlowsFromUsedInInvestingActivities · last filed 2024-10-28

Period endCash Flows From Used In Investing Activities 6 monthCash Flows From Used In Investing Activities 12 month
2023-06-305.17M EUR
6-K · filed 2023-08-07
2022-12-31715.00K EUR
20-F/A · filed 2024-10-28
2022-06-30-2.00K EUR
6-K · filed 2023-08-07
2021-12-31-20.00K EUR
20-F/A · filed 2024-10-28
2020-12-31-13.00K EUR
20-F/A · filed 2024-10-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67